Zacks: Analysts Expect InVivo Therapeutics Holdings Corp. (NVIV) to Announce -$0.16 Earnings Per Share

Equities analysts predict that InVivo Therapeutics Holdings Corp. (NASDAQ:NVIV) will announce earnings per share (EPS) of ($0.16) for the current quarter, Zacks Investment Research reports. Zero analysts have issued estimates for InVivo Therapeutics Holdings Corp.’s earnings. InVivo Therapeutics Holdings Corp. reported earnings per share of ($0.21) in the same quarter last year, which would indicate a positive year over year growth rate of 23.8%. The business is expected to report its next earnings report on Friday, March 9th.

According to Zacks, analysts expect that InVivo Therapeutics Holdings Corp. will report full-year earnings of ($0.81) per share for the current year, with EPS estimates ranging from ($0.83) to ($0.79). For the next fiscal year, analysts anticipate that the company will report earnings of ($0.74) per share, with EPS estimates ranging from ($0.87) to ($0.61). Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side research firms that that provide coverage for InVivo Therapeutics Holdings Corp..

InVivo Therapeutics Holdings Corp. (NASDAQ:NVIV) last announced its quarterly earnings data on Monday, October 30th. The biotechnology company reported ($0.28) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.06).

A number of research analysts have recently issued reports on NVIV shares. Raymond James Financial, Inc. downgraded InVivo Therapeutics Holdings Corp. from an “outperform” rating to a “market perform” rating in a research note on Monday, July 31st. ValuEngine downgraded InVivo Therapeutics Holdings Corp. from a “sell” rating to a “strong sell” rating in a research note on Friday, September 1st.

COPYRIGHT VIOLATION WARNING: This article was originally reported by Markets Daily and is the sole property of of Markets Daily. If you are reading this article on another site, it was illegally stolen and reposted in violation of US and international copyright law. The original version of this article can be read at https://www.themarketsdaily.com/2017/11/15/zacks-analysts-expect-invivo-therapeutics-holdings-corp-nviv-to-announce-0-16-earnings-per-share.html.

Institutional investors and hedge funds have recently modified their holdings of the business. Susquehanna International Group LLP bought a new stake in InVivo Therapeutics Holdings Corp. during the 2nd quarter worth approximately $434,000. Legal & General Group Plc increased its holdings in InVivo Therapeutics Holdings Corp. by 4,427.9% during the 2nd quarter. Legal & General Group Plc now owns 503,407 shares of the biotechnology company’s stock worth $1,359,000 after purchasing an additional 492,289 shares in the last quarter. Goldman Sachs Group Inc. increased its holdings in InVivo Therapeutics Holdings Corp. by 144.5% during the 2nd quarter. Goldman Sachs Group Inc. now owns 167,318 shares of the biotechnology company’s stock worth $452,000 after purchasing an additional 98,879 shares in the last quarter. Blair William & Co. IL bought a new stake in InVivo Therapeutics Holdings Corp. during the 2nd quarter worth approximately $159,000. Finally, LMR Partners LLP bought a new stake in InVivo Therapeutics Holdings Corp. during the 2nd quarter worth approximately $159,000.

Shares of InVivo Therapeutics Holdings Corp. (NVIV) traded up $0.02 during trading hours on Tuesday, hitting $1.27. The stock had a trading volume of 125,200 shares, compared to its average volume of 267,961. InVivo Therapeutics Holdings Corp. has a 12 month low of $1.10 and a 12 month high of $5.90.

InVivo Therapeutics Holdings Corp. Company Profile

InVivo Therapeutics Holdings Corp., formerly Design Source, Inc, is a research and clinical-stage biomaterials and biotechnology company. The Company is engaged in developing and commercializing biopolymer-scaffolding devices for the treatment of spinal cord injuries (SCI). The Company’s approach to treating acute SCIs is based on its investigational Neuro Spinal Scaffold implant, an investigational bioresorbable polymer scaffold that is designed for implantation at the site of injury within a spinal cord contusion and is intended to treat acute spinal cord injury.

Get a free copy of the Zacks research report on InVivo Therapeutics Holdings Corp. (NVIV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for InVivo Therapeutics Holdings Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InVivo Therapeutics Holdings Corp. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply